Topical bactericidal / Anti-acne (keratolytic)
Pregnancy: Considered compatible at topical doses — minimal systemic absorption. Use with caution in first trimester.
Benzoyl Peroxide 2.5–10%
Brand names: PanOxyl (2.5%, 5%, 10% gel/wash), Brevoxyl (4% cream), Duac (benzoyl peroxide 5% + clindamycin 1% — combination)
Adult dose
Dose: Apply once or twice daily to affected areas
Route: Topical (gel, cream, or wash)
Frequency: Once daily initially (increase to twice daily as tolerated)
Max: Apply to affected areas; 10% max concentration
Start with lower concentration (2.5–5%) once daily to minimise irritation. Increase to 5–10% and twice daily after 2–4 weeks if tolerated. Bactericidal against C. acnes (not antibiotic — no resistance). Also keratolytic. Key role in combination to prevent antibiotic resistance.
Paediatric dose
Route: Topical
Frequency: Once daily
Max: 2.5–5% in children; 10% in older adolescents
Concentration: 2.5%, 4%, 5%, 10% Application/ml
Children ≥12 years: use 2.5–5% initially. Avoid near eyes, mouth, nasal mucosa. Avoid in children <12 unless under specialist guidance.
Dose adjustments
Renal
N/A — topical use.
Hepatic
N/A — topical use.
Clinical pearls
- Only topical acne agent that is bactericidal (not bacteriostatic) — C. acnes cannot develop resistance to oxidative mechanism
- Critical for antibiotic resistance prevention — BAD guidelines strongly recommend combining BPO with any topical or oral antibiotic
- Bleaching warning: warn patients about fabric bleaching — white towels and old pillowcases essential; avoid coloured clothing
- Start at 2.5% to minimise irritation; 5% is equally effective in most patients with less irritation than 10%
- Duac gel (BPO + clindamycin): convenient once-daily combination with enhanced efficacy
Contraindications
- Hypersensitivity to benzoyl peroxide
- Application near eyes, mouth, or mucous membranes
Side effects
- Local skin dryness and peeling (very common — dose-dependent)
- Erythema and irritation
- Bleaching of hair, clothing, and bedding (peroxide effect — advise white pillowcase)
- Contact dermatitis (sensitisation — rare)
Interactions
- Topical retinoids (adapalene, tretinoin) — can inactivate each other if used simultaneously; use at different times of day (BPO in AM, retinoid in PM)
- Concurrent topical antibiotics — BPO actively reduces antibiotic resistance when combined (beneficial interaction)
Monitoring
- Skin tolerance (dryness, irritation)
- Acne response at 6–8 weeks
- Contact sensitisation (rare)
Reference: BNFc; BNF; BAD Acne Guidelines 2021; NICE CG184. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Acne Severity Classification (IGA Scale) · Acne
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD